Yasaman Mohtasebi, MD
Endocrinology, Diabetes & Metabolism · Long Beach, CANPI 1962687889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 1,203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,831, 3.5 times the $1,689 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,203 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Novo Nordisk$2K
- Cequr Corporation$2K
- Dexcom, Inc.$2K
- Amgen$2K
- Abbott$2K
- plus $15K from 46 others
What the payments were for
- Food & beverage$27,683100%
- Education$750%
- Other$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$2,059
- FREESTYLE LIBRE 3$381
- Wegovy$363
- DEXCOM G6 TRANSMITTER$362
- UNITY DIABETES MANAGEMENT SYSTEM$316
- REZDIFFRA$262
- TEPEZZA$246
- Kerendia$239
- TZIELD$122
- Cryvista$115
How this compares
$27,778 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 354 | $420,977 |
| TrulicityDulaglutide | 234 | $326,670 |
| RybelsusSemaglutide | 122 | $185,633 |
| JardianceEmpagliflozin | 137 | $170,319 |
| MounjaroTirzepatide | 89 | $110,722 |
| FarxigaDapagliflozin Propanediol | 70 | $78,923 |
| JanuviaSitagliptin Phosphate | 54 | $62,891 |
| SynjardyEmpagliflozin/Metformin Hcl | 58 | $61,387 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $43,254 |
| AfrezzaInsulin Regular, Human | 30 | $40,163 |
| KerendiaFinerenone | 30 | $36,778 |
| TradjentaLinagliptin | 29 | $32,038 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $28,134 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $25,721 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $22,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,108 | $609,416497 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $3,178 | $450,080383 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $1,324 | $263,743224 claims |
| AstraZenecaFarxiga | $701 | $78,92370 claims |
| MerckJanuvia, Janumet | $283 | $71,90269 claims |
| Mannkind CorporationAfrezza | $1,271 | $40,16330 claims |
| BayerKerendia | $1,397 | $36,77830 claims |
| AmgenProlia | $1,995 | $19,61812 claims |
| Cequr CorporationCequr Simplicity | $2,086 | $11,98918 claims |
| AbbVieSynthroid | $727 | $4,31155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Long Beach
- Jennifer ConnellyLong Beach$296K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.